Table 3.
Main Adverse Events Of Enzalutamide, Apalutamide And Darolutamide In The Pivotal Phase III Trials For nmCRPC
| Drug Name | PROSPER Trial32 | SPARTAN Trial33 | ARAMIS Trial34 |
|---|---|---|---|
| Enzalutamide | Apalutamide | Darolutamide | |
| AEs leading to drug discontinuation | 9% vs 6% | 10.7% vs 7% | 8.9% vs 8.7% |
| Grade ≥3 AEs | 31% vs 23% | 24.8% vs 23.1% | 24.7% vs 19.5% |
| AEs (Any grade): | |||
| Fatigue | 33.0% | 30.4% | 12.1% |
| Hypertension | 12.0% | 24.8% | 6.6% |
| Rash | NR | 23.8% | 2.9% |
| Diarrhea | 10.0% | 20.3% | 6.9% |
| Weight loss | 6.0% | 16.1% | 3.6% |
| Falls | 11.0% | 15.6% | 4.2% |
| Mental impairment | 5.0% | 5.1% | 0.9% |
| Seizures | <1% | 0.2% | 0.2% |
Abbreviations: AE, adverse events; NR, not reported.